Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04925648




Registration number
NCT04925648
Ethics application status
Date submitted
23/03/2021
Date registered
14/06/2021
Date last updated
12/04/2023

Titles & IDs
Public title
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Scientific title
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
Secondary ID [1] 0 0
PICASSO
Universal Trial Number (UTN)
Trial acronym
PICASSO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dasatinib
Treatment: Drugs - Darolutamide

Active Comparator: Cohort A - Dasatinib 100mg once daily orally for 14 Days

Active Comparator: Cohort B - Dasatinib 100mg once daily and Darolumatide 600 mg twice daily orally for 14 Days


Treatment: Drugs: Dasatinib
Dasatinib 100mg once daily orally for 14 Days

Treatment: Drugs: Darolutamide
Darolumatide 600 mg twice daily orally for 14 Days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To quantify the increase in tumour (standard uptake value) SUV measurements comparing baseline to 2-week PSMA PET scans in men being treated with dasatinib alone or in combination with darolutamide
Timepoint [1] 0 0
14 days
Secondary outcome [1] 0 0
To determine the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after a 14-day course of dasatinib alone or in combination with darolutamide in men with castrate resistant prostate cancer
Timepoint [1] 0 0
14 days

Eligibility
Key inclusion criteria
1. Male, aged 18 years or older

2. Pathologically confirmed adenocarcinoma of prostate or a clinical presentation
consistent with prostate cancer

3. Metastatic castrate resistant prostate cancer previously confirmed on 68Ga-PSMA-11 and
18F-FDG imaging to be inadequate for future PSMA-directed theranostic treatment by a
nuclear medicine physician based on FDG-discordance (FDG-positive, PSMA-negative sites
of disease) OR low PSMA SUV values within 2 weeks of starting study drug

4. Adequate hematologic and organ function within 14 days before the first study
treatment

5. Castrate levels of testosterone < 1.7 ng/ml

6. Provision of written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patients who cannot lie still for at least 30 minutes or comply with imaging.

2. Previous dasatinib for prostate cancer or other condition, eg CLL

3. Allergy to dasatinib or darolutamide

4. Use of drugs that interact with interact pharmacologically with dasatinib within 1
week of study entry eg Use of CYP3A4 inducers (e.g. dexamethasone, phenytoin,
carbamazepine, rifampicin, phenobarbital or St John's Wort) and use of CYP3A4
substrates with narrow therapeutic index (e.g. astemizole, terfenadine, cisapride,
pimozide, quinidine, bepridil or ergot analogues.

5. Use Concomitant use of H2 antagonists or proton pump inhibitors.

6. Current or previous (within the last 6 months) pleural effusion

7. Use of paracetamol during the study period

8. Subjects may not have any of the following: Clinical evidence of uncontrolled heart
failure, myocardial infarction, or angina within the previous 6 months; prolonged QT
interval Fridericia's (QTcF) > 450msec; history of unstable ventricular arrhythmias
(ventricular tachycardia, ventricular fibrillation, or torsades de pointes);
concomitant use of drugs known to cause torsades de pointes [quinidine, procainamide,
disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins,
clarithromycin, chlorpromazine, haloperidol, mesoridazine,thioridazine, pimozide,
cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone,
halofantrine, levomethadyl,pentamidine, sparfloxacin, lidoflazine] (these agents must
have been discontinued at least 7 days prior to starting dasatinib)

9. Subjects may not be enrolled with any of the following: History of a significant
bleeding disorder unrelated to cancer, including diagnosed congenital bleeding
disorders (e.g., von Willebrand's disease), and diagnosed acquired bleeding disorder
within one year (e.g., acquired anti-factor VIII antibodies); GI bleeding from any
cause within 3 months

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2025
Actual
Sample size
Target
22
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Kinghorn Cancer Centre, St. Vincent's Hospital - Sydney
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
3000 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
St Vincent's Hospital, Sydney
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study's purpose is to understand the appearance of your prostate-specific membrane
antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib
alone or in combination with anti-testosterone drug call darolutamide.

Who is it for? You may be eligible to join this study if you have metastatic prostate cancer
and had a recent PSMA scan showing low PSMA uptake

Study Details:

Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide
600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days.
Participants will be followed up on day 7 of treatment and 30 days after treatment.

It is hoped that this research will provide insight into the mechanism of PSMA expression in
advanced prostate cancer.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04925648
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Anthony Joshua, FRACP, MBBS, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 293555655
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04925648